Skip to main content

Research Repository

Advanced Search

Thinking around abdominal obesity and cardiovascular risk.

Broom, Iain

Authors

Iain Broom



Abstract

Obesity, particularly intra-abdominal (visceral) obesity, is a leading cause of cardiovascular disease (CVD), insulin resistance, type 2 diabetes, dyslipidaemia, inflammation and thrombosis. A useful indicator for visceral fat is waist circumference, which is associated with all-cause mortality. Pro-inflammatory adipokines play a causal role in the development of pathologies associated with insulin resistance, type 2 diabetes and CVD. In addition to established anti-obesity therapies, namely orlistat and sibutramine, a new type of agent that inhibits the cannabinoid receptor (CB1) is advanced in development to reduce appetite and act predominantly against intra-abdominal adiposity.

Citation

BROOM, I. 2006. Thinking around abdominal obesity and cardiovascular risk. British journal of diabetes and vascular disease, 6(2), pages 58-61.

Journal Article Type Article
Acceptance Date Mar 31, 2006
Online Publication Date Mar 31, 2006
Publication Date Mar 31, 2006
Deposit Date Dec 6, 2012
Publicly Available Date Dec 6, 2012
Journal British journal of diabetes and vascular disease
Print ISSN 1474-6514
Electronic ISSN 1753-4305
Publisher SAGE Publications
Peer Reviewed Peer Reviewed
Volume 6
Issue 2
Pages 58-61
DOI https://doi.org/10.1177/14746514060060020301
Keywords Abdominal obesity; Metabolic syndrome; Visceral fat; Waist circumference; Cardiometabolic risk
Public URL http://hdl.handle.net/10059/783

Files





You might also like



Downloadable Citations